Abstract:Background Hypertrophic cardiomyopathy (HCM) is a vastly heterogeneous sarcomere disorder unified by maximal left ventricular (LV) thickness increases. The lifetime relative risk of morbidity in HCM is four-fold higher than in the general population, primarily driven by arrhythmias and heart failure (HF). Numerous prognostic features have been identified, but our ability to identify high-risk patients of progression remains rudimentary. Small retrospective studies have shown that systemic inflammation is associated with adverse outcomes in patients with HF; others, small and single-center, have also shown associations between adverse outcomes and inflammation in HCM. Purpose We aimed to determine whether elevated levels of inflammatory biomarkers are associated with an increased risk of acute heart failure (AHF) and mortality at 1 year in a large cohort of patients with HCM across multiple centers in the United States (US). Methods In this retrospective study, using the US cohort of 60 healthcare organizations in the TriNetX database, we included more than 85,000 adult patients with HCM (ICD-10-CM codes I42.1 and I42.2) between 2004 and 2024. Patients were divided according to predetermined cut-offs of different inflammatory biomarkers (C-reactive protein [CRP], <2 mg/L vs. 2-100 mg/L; white blood cells [WBC], < vs. ≥ the median [8x10^3/μL]; neutrophils [Neu], < vs. ≥ the median [5x10^3/μL]). These cohorts were then 1:1 propensity score matched (PSM) for age, sex, and race. We used Kaplan-Meier survival curves to derive cumulative incidence curves (as 1 minus Kaplan-Meier survival estimates) for AHF (ICD-10-CM codes I50.21, I50.23, I50.31, I50.33, I50.41, I50.43) or death, and we compared them with the Log-rank (Mantel-Cox) test. We also derived Hazard Ratios (HR) with 95% Confidence Interval (CI) from Cox regression analysis to compare the outcomes within the groups at 1-year. Results After PSM, patients with HCM and CRP levels between 2-100 mg/L experienced higher rates of the composite outcome (19.6% vs. 12.2%, Log-rank p<0.001; HR 1.67, 95% CI [1.29-2.16]), as well as the separate outcomes of death (14.7% vs. 6.8%, Log-rank p<0.001; HR 2.23, 95% CI [1.68-2.98]) and AHF (10.9% vs. 7.5%, Log-rank p<0.001; HR 1.49, 95% CI [1.07-2.07]), compared to those with CRP <2 mg/L (Table 1)(Figure 1). Similarly, patients with Neu ≥5x10^3/μL reported higher incidences of the composite outcome (20.3% vs. 13.2%, Log-rank p<0.001; HR 1.62, 95% CI [1.55-1.68]) and the separates outcomes, compared to those with Neu <5x10^3/μL (Table 1) (Figure 1). Patients with WBC ≥8x10^3/μL also had increased rates of the composite outcome (19.4% vs. 14.1%, Log-rank p<0.001; HR 1.43, 95% CI [1.38-1.48]) and the separate outcomes, compared to those with WBC <8x10^3/μL (Table 1)(Figure 1). Conclusions In the first large 'real world' analysis of patients with HCM, elevated levels of inflammatory biomarkers were associated with worse outcomes of death and acute heart failure.

The Outcome Of Acute Heart Failure In Patients With Hypertrophic Obstructive Cardiomyopathy

Temporal Trends, Prevalence, Predictors, and Outcomes of Heart Failure in Patients with Hypertrophic Cardiomyopathy in the United States: Insights from the National Inpatient Sample

Long-term clinical outcomes in patients with hypertrophic cardiomyopathy versus hypertensive heart disease

Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry

The Outcome Of Acute Heart Failure In Patients With Pulmonary Embolism, A Nationwide Analysis

Clinical Characteristics and Outcomes in Patients With Apical and Nonapical Hypertrophic Cardiomyopathy

Outcomes Of Heart Failure Hospitalization In Patients With Housing-related Problems: A Nationwide Analysis

Maternal And Fetal Outcomes In Patients With Hypertrophic Cardiomyopathy

Endovascular Transcatheter Aortic Valve Replacement Outcomes in Hypertrophic Cardiomyopathy: Insights from the National Inpatient Sample (2014-2018)

An Analysis on Clinical Characteristics and Prognosis of Obstructive and Non-Obstructive Hypertrophic Cardiomyopathy

The Outcome Of Acute Heart Failure In Patients With History Of Heart Transplant: A Nationwide Analysis

Prevalence of cardiovascular comorbidities among hospitalized patients with hypertrophic cardiomyopathy and factors associated with a higher case-fatality rate

One-year outcomes of patients with hypertrophic cardiomyopathy according to levels of inflammatory biomarkers

Heart Failure In Adults With History Of Congenital Heart Disease

The Outcome Of Acute Heart Failure In Patients With History Of Portal Hypertension: A Nationwide Analysis

Heart Failure With Stable Mildly-reduced Ejection Fraction: Prognosis and Predictors of Outcomes

Heart failure risk assessment in patients with hypertrophic cardiomyopathy based on the H2FPEF score

Long-Term Outcomes of Heart Failure With Preserved or Mid-Range Ejection Fraction in the United States

Atrial Fibrillation in Hypertrophic Cardiomyopathy: Prevalence, Clinical Correlations, and Mortality in a Large High‐Risk Population

Heart failure burden among adults with congenital heart disease

Clinical Significance of Overweight in Patients with Hypertrophic Cardiomyopathy: A Retrospective Cohort Study.